Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

Reaction to dexamethasone treatment for Covid-19 patients

Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said: “It is hugely encouraging that the UK’s largest clinical trial researching Covid-19 treatments has shown such positive results for the generic medicine dexamethasone. As it is an existing medicine, dexamethasone can potentially be rolled out very quickly with the NHS as a treatment option for seriously ill Covid patients. We mustn’t lose sight of the innovation that repurposed generic medicines for new clinical uses can provide as part of the solution to combating Covid-19. Off-patent medicines can offer immediate, low-cost and high volume options which could potentially save many, many lives.”